# Is Ipamorelin FDA-Approved? Regulatory Status | Ipamorelin

> Is ipamorelin FDA approved? No. Ipamorelin has never been approved as a drug; its one Phase 2 trial failed and 2024 FDA action restricted compounding access.

Short answer: no. Never approved, anywhere. One failed trial, no Phase 3, and a 2024 tightening of compounding access.

## The short version

The question "is ipamorelin fda approved" has a one-word answer: no. Ipamorelin has never been approved as a drug by the FDA, the European Medicines Agency, or any other regulator, for any condition. It is not a prescription medicine and it is not an over-the-counter product. It is sold as a "research chemical."

It was not ignored — it was tested and it did not clear the bar. One mid-stage human trial, for slow bowel recovery after surgery, missed its goal [3]. No later trials followed. In 2024 the FDA also made it harder for compounding pharmacies (which custom-mix medicines) to use it. So the status is not "still under review." It is "tested, fell short, never approved."

## Never approved — and why that matters

Ipamorelin has no approved indication in any country. The lack of approval is not a paperwork gap; it reflects a clinical program that stalled on evidence. The compound was discovered at Novo Nordisk in the 1990s, characterized for selectivity in 1998 [1], and had its human pharmacokinetics mapped in 1999 [2]. It then advanced into clinical development for one indication — postoperative ileus — and went no further once that trial read out.

## The one human trial that decided it

The only published Phase 2 randomized controlled trial (NCT00672074) gave 0.03 mg/kg intravenously twice daily, for up to seven days, to 114 adults recovering from bowel resection. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that was not statistically significant (p=0.15) [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of placebo — no ipamorelin-specific safety alarm in that short window, but no efficacy either. No Phase 3 trial has ever been run. That single negative result is the human efficacy record.

## The 2024 compounding restriction

Compounding pharmacies operate under Section 503A of the federal drug law, which lets them mix drugs from approved or specifically listed bulk substances. Ipamorelin acetate had sat on the interim 503A Category 2 list. In September 2024 the nominator withdrew it, and the FDA removed ipamorelin acetate from Category 2. The agency then reviewed both ipamorelin acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting. The practical effect: ipamorelin is not an approved bulk substance for compounding, narrowing the legitimate pharmacy route that some clinics had relied on.

## Banned in sport, separately

Regulatory status and anti-doping status are two different ledgers, and ipamorelin fails both. It is prohibited in sport at all times under the WADA Prohibited List category S2 (peptide hormones, growth factors, related substances, and mimetics), as a growth hormone secretagogue, and it is detectable in urine by accredited laboratories [11]. A 2026 critical review of peptide use in sport flagged its short half-life as an analytical challenge for detection while noting the expanding WADA framework around it [11]. Anti-doping chemists have also identified modified black-market versions — a glycine-tagged Gly-Ipamorelin confirmed by high-resolution mass spectrometry [9], later found in seized doping material [10].

## So where does that leave it

Tested, unproven, unapproved, restricted, and banned in sport. The compound has real and well-characterized pharmacology — a clean, selective GH pulse [1] — but pharmacology is not approval. No regulator has cleared it for use, the human efficacy evidence is one failed trial, and there is no long-term human safety database to point to. Read the [research](/research) for the mechanism and the studies, and the [effects](/effects) page for what people report against that thin clinical backdrop.

---

A terminal-plain readout of where ipamorelin stands with regulators — never approved, banned in sport, compounding restricted, each line logged to source; no clinic behind the console and nothing here stocked, dispensed, or sold.